CombinatoRx, Incorporated Announces Portfolio Advancements
CAMBRIDGE, Mass.--(BUSINESS WIRE)--CombinatoRx, Incorporated (NASDAQ: CRXX) today announced updates to its portfolio of product candidates for 2007 including the decision to move two product candidates, CRx-102 and CRx-170, into later stage clinical development and to add three new product candidates, CRx-191, CRx-197 and CRx-401 into clinical development from its preclinical pipeline.